Dr. Yajun Xu is a seasoned biotech investor with more than 20 years of senior management experience in Biotech and pharma. Yajun is currently a managing partner of Hongsen Capital, a co-founder of Epimab Inc., and serves as a board member and advisor for numerous biotech companies and investment firms in U.S. and China.

Yajun has previously served as the President of Shangpharma Investment Group, as Senior Vice President of Corporate Development of Shangpharma, as Vice President of Biology and Pre-Clinical Services at Chempartner (a Shangpharma affiliate), as Director of Inflammation at Millennium Pharma Inc., and as Senior Scientist at BASF Bioresearch Corp. (now AbbVie Bioresearch Corp.).

Yajun received her Ph.D. in Biochemistry at Brandeis University and completed her postdoctoral training at Harvard University School of Public Health.